Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05100862 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Study acronym: MAHOGANY
StatusActive, Not Recruiting
PhasePhase 3
Started2022-03-10
View on ClinicalTrials.gov ↗

Amendment history

The 50 most recent of 63 record versions are listed below. See every version on ClinicalTrials.gov ↗

2026-09-09
Study Status, Contacts/Locations v62
Study sites266→264
2026-08-18
Study Status, Contacts/Locations v61
Study sites268→266
2026-08-05
Study Status, Contacts/Locations v60
Study sites270→268
2026-07-22
Study Status, Contacts/Locations v59
Trial sites expanded: 257 → 270 locations
2026-07-14
Study Status, Study Design, Contacts/Locations v58
Trial status changed: Recruiting → Active, Not Recruiting
Trial sites reduced: 277 → 257 locations
Enrollment targetestimated 780→confirmed 799
2026-06-17
Study Status, Contacts/Locations v57
Study sites277 entries, revised
Clinical Research Alliance, IncOPTUM
2026-06-09
Study Status, Sponsor/Collaborators, Study Description, Contacts/Locations, IPDSharing v56
Sponsor changed: BeiGene → BeOne Medicines+8 characters
WasBeiGene
NowBeOne Medicines
Study description+209 characters
Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.
Study sitesdetails revised at 8 of 277 sites
2026-05-26
Study Status, Contacts/Locations v55
Study sitesdetails revised at 2 of 277 sites
2026-05-08
Study Status, Contacts/Locations v54
Study sites277 entries, revised
Hospital Sao RafaelinstitutoRafael Instituto Dor de Pesquisa E Ensino
2026-04-20
Study Status, Contacts/Locations v53
Study sitesdetails revised at 1 of 277 sites
2026-03-17
Study Status, Contacts/Locations v52
Study sites277 entries, revised
Hopital Larchet 2 Chu Nice Szpital Uniwersytecki Nr 2 Im Dr Jana Biziela
2026-02-20
Study Status, Contacts/Locations v51
Study sites258→277
2026-01-09
Study Status, Contacts/Locations v50
Study sites259→258
2025-11-19
Study Status, Contacts/Locations v49
Study sitesdetails revised at 2 of 259 sites
2025-11-07
Study Status, Contacts/Locations v48
Study sites256→259
2025-10-23
Study Identification, Study Status, Contacts/Locations v47
Study sites259→256
2025-09-19
Study Status, Contacts/Locations v46
Study sites265→259
2025-09-11
Study Status, Contacts/Locations v45
Study sitesdetails revised at 27 of 265 sites
2025-08-19
Study Status, Contacts/Locations v44
Study sites289→265
2025-06-23
Study Status, Contacts/Locations v43
Study sitesdetails revised at 10 of 289 sites
2025-06-04
Study Status, Contacts/Locations v42
Study sites291→289
2025-04-29
Study Status, Contacts/Locations v41
Study sites294→291
2025-04-17
Study Status, Study Design v40
Enrollment target750→780
2025-04-10
Study Status, Contacts/Locations v39
Study sites287→294
2025-03-21
Study Status, Contacts/Locations v38
Study sites290→287
2025-03-07
Study Status, Contacts/Locations v37
Study sites298→290
2025-02-14
Study Status, Contacts/Locations, IPDSharing v36
Study sites300→298
2025-01-28
Study Status, Contacts/Locations v35
Study sites295→300
2025-01-09
Study Status, Contacts/Locations v34
Study sites294→295
2024-12-13
Study Status, Contacts/Locations v33
Study sitesdetails revised at 1 of 294 sites
2024-12-04
Study Status, Contacts/Locations v32
Study sites175→294
2024-10-25
Study Status, Contacts/Locations v31
Study sites237→175
2024-10-17
Study Status, Contacts/Locations v30
Study sites253→237
2024-09-27
Study Status, Contacts/Locations v29
Study sites244→253
2024-09-04
Study Status, Eligibility, Contacts/Locations, IPDSharing v28
Study sites236→244
Eligibility criteria+143 characters
[...] rial, and/or viral infection that requires systemic therapy Prior treatment with lenalidomide or drug from same class, if without response (partial or complete) or short remission duration (< 24 months) Note: Other protocol defined Inclusion/Exclusion criteria may apply.
2024-08-19
Study Status, Contacts/Locations v27
Study sites228→236
2024-07-30
Study Status, Contacts/Locations v26
Study sites224→228
2024-07-16
Study Status, Contacts/Locations v25
Study sites216→224
2024-07-08
Study Status, Contacts/Locations v24
Study sites203→216
2024-06-05
Study Status, Contacts/Locations v23
Study sites181→203
2024-05-17
Study Status, Contacts/Locations v22
Study sites171→181
2024-04-23
Study Status, Contacts/Locations v21
Study sites154→171
2024-03-12
Study Identification, Study Status, Arms and Interventions, Outcome Measures, Eligibility, Contacts/Locations v20
Primary completion date2028-08→2028-07
Completion date2029-06→2030-06
Study sites137→154
Eligibility criteria+4 characters
Key Inclusion Criteria: Histologically confirmed grade 1-3a FL or MZL Previously receivedtreated with ≥ 1 line of systemic therapy including anti-CD20 agent. Mus [...]
Secondary endpoints11 entries, revised
Duration Of Response As Determined By An Independent Review CommitteeBIRC And By Investigator Assessment . Overall Response Rate As Determined By An Independent Review CommitteeBIRC And By Investigator Assessment Complete Response Rate As Determined By An Independent Review CommitteeBIRC And By Investigator Assessment Time To Response As Determined By An Independent Review CommitteeBIRC And By Investigator Assessment
Primary endpoints1 entry, revised
Progression-free Survival As Determined By AnA Blinded Independent Review Committee (BIRC)
2024-01-31
Study Status, Contacts/Locations v19
Study sites115→137
2024-01-11
Study Status, Contacts/Locations v18
Study sites87→115
2024-01-04
Study Status, Contacts/Locations v17
Study sites71→87
2023-12-01
Study Status, Contacts/Locations v16
Study sites54→71
2023-11-08
Study Identification, Study Status, Contacts/Locations v15
Study sites43→54
2023-10-25
Study Status, Contacts/Locations v14
Study sites33→43
2023-09-26
Study Status, Contacts/Locations v13
Study sites34→33
The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R\^2 in participants with R/R marginal zone lymphoma (MZL), as measured by progression free survival (PFS) assessed by IRC in accordance with CT-based Lugano 2014 Criteria.
Trial Details
NCT Number NCT05100862
Lead Sponsor BeOne Medicines
Conditions Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
Enrollment 799 participants
Start Date 2022-03-10
Primary Completion 2028-07 (estimated)
Study Completion 2030-06 (estimated)
Updated on ClinicalTrials.gov 2026-09-28